GPT and metabolic dysfunction-associated steatotic liver disease: AST and ALT were confirmed to be significantly decreased in NAFLD patients who received pioglitazone therapy (AST: I2 = 51%, MD = −6.56, 95% CI: (−11.18) - (−1.94), P < 0.01; ALT: I2 = 71%, MD = −14, 95% CI: (−23.75) - (−4.26), P < 0.01; Supplementary Figure 1).